Compare IVDA & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVDA | SBFM |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 4.3M |
| IPO Year | 2015 | 2008 |
| Metric | IVDA | SBFM |
|---|---|---|
| Price | $0.29 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 8.4M | 388.2K |
| Earning Date | 05-12-2026 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.38 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,468,279.00 | ★ $36,305,891.00 |
| Revenue This Year | N/A | $40.47 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 132.98 | 4.11 |
| 52 Week Low | $0.21 | $0.25 |
| 52 Week High | $2.24 | $3.05 |
| Indicator | IVDA | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 36.73 |
| Support Level | $0.27 | $0.27 |
| Resistance Level | $0.34 | $1.29 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 25.08 | 23.33 |
Iveda Solutions Inc offers smart city technologies globally, offering AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products). Geographically, the company operates in USA and Taiwan, majority of its revenue is generated from Taiwan.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.